Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of...

|About: The Medicines Company (MDCO)|By:, SA News Editor

Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of the drug developer's previously announced positive results for the Phase III trial of oritavancin. The firm now sees it as a takeout candidate and reiterates an Outperform. Separately, JPMorgan also ups the shares to Overweight.